MP-4-CO(MP-4-CO) - 药物靶点：Hemoglobins_专利_临床

概要

基本信息

药物类型

生物药

别名

PEG carboxyhaemoglobin、Pegylated carboxyhaemoglobin

靶点

Hemoglobins

作用机制

血红蛋白调节剂

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病

在研适应症-

非在研适应症

血红蛋白SC疾病血管闭塞危机

原研机构

Sangart, Inc.

在研机构-

非在研机构

Sangart, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

关联

2

项与 MP-4-CO 相关的临床试验

NCT01925001 / Withdrawn临床2期

A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease

Sickle Cell disease is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body. In Sickle Cell disease, as red blood cells circulate and oxygen is released, the deoxygenated abnormal Hemoglobin S can begin to polymerize and cause red cells to become sticky and elongated. These "sickled" red cells are less flexible and will obstruct small blood vessels and prevent normal red cells from circulating freely, which limits oxygen delivery to tissues and organs. This is known as a "sickling crisis" or "vaso-occlusive crisis" and is the leading cause of hospitalization in patients with Sickle Cell disease.
Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death. Current therapy is limited to hydration and symptomatic pain relief. The administration of MP4CO as an adjunct treatment to standard therapy may alleviate pain associated with a sickling crisis and potentially reduce the severity and duration of a crisis. This may shorten the time in hospital and potentially improve the quality of life for patients with sickle cell anemia.

开始日期2013-10-01

申办/合作机构

Sangart, Inc.

NCT01356485 / Completed临床1期

A Multi-center, Randomized, Double Blind, Dose Escalation Safety Study of MP4CO in Clinically Stable Adult Sickle Cell Patients

Sickle Cell Anemia is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body. In sickle cell disease, as red blood cells circulate and oxygen is released in the circulatory system, the deoxygenated abnormal hemoglobin S can begin to polymerize. When this occurs, the red blood cells can become sticky and elongated. These sickled red blood cells are less flexible and will obstruct small blood vessels and block normal red blood cells from traveling through the circulatory system, which limits oxygen delivery to tissues and organs. This is known as a "sickle crisis".
Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death. By lowering the level of oxygen pressure at which sickling occurs and opening the vasculature and rapidly delivering oxygen directly to ischemic tissues, the addition of MP4CO to existing treatment protocols may alleviate pain associated with a sickle cell crisis, abort a crisis and/or potentially reduce the duration of a crisis. This could mean less time in the hospital and an improved quality of life for patients with sickle cell anemia.

开始日期2012-01-01

申办/合作机构

Sangart, Inc.

100 项与 MP-4-CO 相关的临床结果

登录后查看更多信息

100 项与 MP-4-CO 相关的转化医学

登录后查看更多信息

100 项与 MP-4-CO 相关的专利（医药）

登录后查看更多信息

16

项与 MP-4-CO 相关的文献（医药）

2024-10-01·Journal of Applied Physiology

Coadministration of PEGylated apohemoglobin and haptoglobin can limit vascular dysfunction in the microcirculation and prevent acute inflammation

Article

作者: Muller, Cynthia R. ; O’Boyle, Quintin ; Cabrales, Pedro ; Pires, Ivan S. ; Lucas, Daniela ; Palmer, Andre F. ; Martinez, Jacinda ; Munoz, Carlos J.

Coadministration of PEGylated human apohemoglobin (PEG-apoHb)—a hemopexin (Hpx) mimetic that can scavenge free heme—and human plasma-derived haptoglobin (Hp) that can scavenge hemoglobin (Hb), reduces microcirculatory dysfunction and cardiac and kidney inflammation in a Hb-challenge model.

2020-08-14·Military Medicine4区 · 医学

Improved Hemodynamic Recovery and 72-Hour Survival Following Low-Volume Resuscitation with a PEGylated Carboxyhemoglobin in a Rat Model of Severe Hemorrhagic Shock

4区 · 医学

Article

作者: Song, Bjorn K ; Nugent, William H ; Sheppard, Forest R ; Macko, Antoni ; Abuchowski, Abe

AbstractIntroduction: Hemorrhage is a leading cause of death from potentially survivable civilian and military trauma. As projected conflicts move from settings of tactical and logistical supremacy to hyper-dynamic tactical zones against peer and near-peer adversaries, protracted medical evacuation times are expected. Treatment at the point-of-injury is critical. Although crystalloids like Lactated Ringer’s (LR) are ubiquitous, whole blood (WB) is the preferred resuscitation fluid following hemorrhage; however, logistical constraints limit the availability of WB in prehospital settings. Hemoglobin-based oxygen carriers (HBOCs) offer both hemodynamic support and oxygen-carrying capacity while avoiding logistical constraints of WB. We hypothesized that low-volume resuscitation of severe hemorrhagic shock with an HBOC (PEGylated carboxyhemoglobin, [PC]) would improve hemodynamic recovery and 72-hour survival; comparable to WB and superior to LR. Materials and Methods: A total of 21 anesthetized male Sprague-Dawley rats underwent severe hemorrhagic shock followed by randomly assigned low-volume resuscitation with LR, WB, or PC, and then recovered from anesthesia for up to 72-hour observation. Mean arterial pressure (MAP) was recorded continuously under anesthesia, and arterial blood gases were measured at baseline (BL), 60 minutes post-hemorrhage (HS1h), and 24 hours post-resuscitation (PR24h). Survival was presented on a Kaplan–Meier plot and significance determined with a log-rank test. Cardiovascular and blood gas data were assessed with one-way analysis of variance and post hoc analysis where appropriate. Results: All measured cardiovascular and blood chemistry parameters were equivalent between groups at BL and HS1h. BL MAP values were 90 ± 3, 86 ± 1, and 89 ± 2 mmHg for LR, PC, and WB, respectively. Immediately following resuscitation, MAP values were 57 ± 4, 74 ± 5, and 62 ± 3 mmHg, with PC equivalent to WB and higher than LR (P < 0.05). WB and LR were both lower than BL (P < 0.0001), whereas PC was not (P = 0.13). The PC group’s survival to 72 hours was 57%, which was not different from WB (43%) and higher than LR (14%; P < 0.05). Conclusions: A single bolus infusion of PC produced superior survival and MAP response compared to LR, which is the standard fluid resuscitant carried by combat medics. PC was not different from WB in terms of survival and MAP, which is encouraging because its reduced logistical constraints make it viable for field deployment. These promising findings warrant further development and investigation of PC as a low-volume, early treatment for hemorrhagic shock in scenarios where blood products may not be available.

2020-06-01·Journal of Pharmacy Practice

Early Experiences With PEGylated Carboxyhemoglobin Bovine in Anemic Jehovah’s Witnesses: A Case Series and Review of the Literature

Review

作者: Wahby, Krista ; McConachie, Sean ; Almadrahi, Zinah ; Wilhelm, Sheila

Jehovah’s Witnesses (JW) represent a complex patient population due to their refusal to accept blood transfusions on religious grounds. Pharmacologic management of anemic JW patients is limited to stimulation of hematopoiesis by iron and erythropoietin supplementation and reduction of blood loss by prothrombin complex concentrates (PCCs). Hemoglobin-based oxygen carriers (HBOCs) represent the only pharmacologic modality for JW patients capable of acutely increasing a patient’s oxygen carrying capacity in the setting of organ failure, yet clinical safety and efficacy data are lacking in this population. We report 3 cases in which the HBOC, PEGylated carboxyhemoglobin bovine (Sanguinate®), was requested under emergent circumstances for severely anemic (hemoglobin <5 g/dL) JW patients who refused blood transfusions. Two patients received PEGylated carboxyhemoglobin infusions for severe anemia, while the third patient died prior to receiving the medication. One patient who received Sanguinate died after 5 units of medication. The other patient’s hemoglobin recovered and she was discharged in stable condition. This series demonstrates the complex nature of the critically anemic JW population and highlights the clinical considerations of using HBOCs in clinical practice and the critical need for further research before they can be broadly recommended.

100 项与 MP-4-CO 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血红蛋白SC疾病	临床2期	巴林	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	荷兰	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	黎巴嫩	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	英国	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	巴西	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	土耳其	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	法国	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	临床2期	比利时	Sangart, Inc.	2013-10-01
血管闭塞危机	临床2期	巴西	Sangart, Inc.	2013-10-01
血红蛋白SC疾病	药物发现	卡塔尔	Sangart, Inc.	2013-10-01